.Sanofi is actually still set on taking its own several sclerosis (MS) med tolebrutinib to the FDA, execs have actually informed Tough Biotech, in spite
Read moreSanofi’s $80M bank on Key dystrophy medication finishes in phase 3 crash
.Simply four months after Sanofi wager $80 million in upfront cash on Key Therapies’ losmapimod, the plan has actually finished in a stage 3 failing.The
Read moreSanofi picks brand new CSO from in-stealth biotech
.After a handful of years in biotech, Mike Quigley, Ph.D., is going back to the pharma fold, occupying the top scientific research place at Sanofi.Quigley
Read moreSanofi pays for $110M upfront for late-stage radioligand therapy
.Sanofi has created a late access to the radioligand party, paying for 100 million europeans ($ 110 million) upfront for global civil liberties to a
Read moreSanofi fails MS study, inflicting another blow to Denali contract
.Sanofi has actually ceased a phase 2 hardship of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 prevention hardship from its
Read moreSangamo slashes time to market for Fabry genetics treatment as FDA accepts to sped up authorization deal
.Sangamo Therapeutics has actually recognized a quick way to market for its own Fabry health condition candidate, aligning with the FDA on a process that
Read moreSage lays off half of R&D group as well as shocks C-suite once more
.Sage Rehabs’ most recent effort to shrink its pipe and labor force will certainly see a 3rd of the biotech’s staff members heading for the
Read moreRoivant reveals brand new ‘vant’ to progress Bayer hypertension med
.Matt Gline is actually back with a brand-new ‘vant’ company, after the Roivant Sciences chief executive officer spent Bayer $14 thousand ahead of time for
Read moreRoche wagers around $1B to broaden Dyno gene treatment distribution deal
.After developing a gene therapy collaboration with Dyno Rehabs in 2020, Roche is back for more.In a new offer likely worth much more than $1
Read moreRoche is actually supporting out chances that its own injectable weight problems possibility might ultimately show 25% effective weight loss in late-stage trial
.Roche is holding out chances that its own injectable weight problems prospect could ultimately display 25% fat burning in late-stage tests, the pharma’s mind of
Read more